Large-cap stocks, valued over $10 billion, offer stability and are considered safer during bear markets. Investing in large-cap exchange-traded funds (ETFs) like the Vanguard S&P 500 ETF provides ...

Small-cap stocks, valued between $300 million-$2 billion, often yield high growth but carry more risk. Recent interest rate cuts may bolster small-cap stocks' performance over large caps.

Now, it’s time to look ahead to 2025. Here is the outlook for the Packers in terms of the salary cap, free agency, the NFL Draft and team needs. During the offseason, only the 51 most-expensive ...

Most discussion of whether there’s a market bubble is entered around the technology sector. But investors may want to look further afield. So says True Contrarian blog and newsletter’s chief ...

Intra-Cellular Therapies ITCI signed a definitive agreement with pharma bigwig Johnson & Johnson JNJ. Per the terms, the pharma giant will acquire all outstanding shares of ITCI for $132 per share ...

本文来自：华尔街见闻，作者：张雅琦，原文标题：《近两年来最大生物技术并购！强生百亿收购Intra-Cellular，后者盘前飙升近38%》 强生收购Intra-Cellular，将目光瞄准中枢神经系统疾病市场。 1月13日，强生公司以146亿美元收购Intra-Cellular Therapies，以增强其在神经 ...

In her State of the State address Tuesday, New York Democratic Gov. Kathy Hochul is expected to lay out her "Cap & Invest" anti-pollution program that critics warn will cause gasoline and utility ...

Johnson & Johnson will acquire Intra-Cellular for $132 per share in cash, a 39 percent premium over Intra-Cellular's Friday closing price of $94.87. Following the announcement, shares of both ...

Commissions do not affect our editors' opinions or evaluations. Small-cap stocks offer big advantages for your investment portfolio. Nimble, small companies grow faster than large-cap firms ...

8, 2024. (AP Photo/Ted Shaffrey, File) Updated [hour]:[minute] [AMPM] [timezone], [monthFull] [day], [year] Johnson & Johnson will spend more than $14 billion to delve further into the treatment of ...

Mario Tama / Getty Images Shares of Intra-Cellular Therapies jumped Monday morning after Johnson & Johnson announced plans to buy the biopharmaceutical company. Intra-Cellular shareholders will ...